Renal protective effect of metabolic therapy in patients with coronary artery disease and diabetes: From bench to bed side

Current Pharmaceutical Design

Volumn 15, Issue 8, 2009, Pages 863-882

  Thuillier, Raphael ^a,e   Tillement, Jean Paul ^b   Hauet, Thierry ^a,c,d  

^a INSERM   (France)

^b ACADÉMIE NATIONALE DE MÉDECINE   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d CEMAGREF   (France)

^e UNIVERSITÉ DE POITIERS   (France)

Author keywords

Cold preservation; Coronary artery disease; Diabetes; Metabolic therapy; Renal failure; Renal ischemia reperfusion injury; Renal protection; Trimetazidine

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; AMIODARONE; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOSPORIN A; DICHLOROACETIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MANGANESE SUPEROXIDE DISMUTASE; PERHEXILINE; RANOLAZINE; THROMBOCYTE ACTIVATING FACTOR; TRIMETAZIDINE; TUMOR NECROSIS FACTOR; UBIDECARENONE; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; ANATOMICAL VARIATION; ANGINA PECTORIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROTIC PLAQUE; CARDIOMYOPATHY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COLD ISCHEMIA; CONGESTIVE HEART FAILURE; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; GLYCOLYSIS; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY ALLOGRAFT REJECTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; MICROSCOPIC ANATOMY; NEPHRON; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; RISK FACTOR; SMOKING;

CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HUMANS; KIDNEY FAILURE, ACUTE; LIVER; OXIDATIVE STRESS; PROTECTIVE AGENTS; RENAL INSUFFICIENCY, CHRONIC; REPERFUSION INJURY; RISK FACTORS; VASODILATOR AGENTS; WARM ISCHEMIA;

EID: 65649116546     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582110     Document Type: Review

References (211)

1. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: Insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008; 121(9): 748-57.
2. Rysz J SRA. The nephroprotective potential of trimetazidine in chronic inflammation and oxidative stress in renal disease. Arch Med Sci 2007; 3(3A): S57-8.
3. Andreoli TC, Griggs C, Loscalzo R, Cecil J. Essentials Medicine. Philadelphia, PA: Saunders 2007.
4. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics - 2008 update: A report from the Am Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circ 2008; 117(4): E25-146.
5. Thomas AC, Knapman PA, Krikler DM, Davies MJ. Community study of the causes of "natural" sudden death. BMJ (Clin Res ed) 1988; 297(6661): 1453-6.
6. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997; 34(1): 25-33
7. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57(6): 1446-54.
8. Wierzbicki AS, Nishtar S, Lumb PJ, Lambert-Hammill M, Crook MA, Marber MS, et al. Impaired renal function and atherosclerosis in a Pakistani cohort. Curr Med Res Opin 2005; 21(8): 1201-7.
9. Fioretto P, Caramori ML, Mauer M. The kidney in diabetes: Dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia 2008; 51(8): 1347-55.
10. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Cclin Pract 2008; 4(8): 444-52.
11. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352(9123): 213-9.
12. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ (Clin Res ed) 2000; 321(7274): 1440-4.
13. Abaci A, Sen N, Yazici H, Tulmac M, Turkoglu S, Tavil Y, et al. Renal dysfunction is the most important predictor of the extent and severity of coronary artery disease in patients with diabetes mellitus. Coron Artery Dis 2007; 18(6): 463-9.
14. Garwood S. Renal insufficiency after cardiac surgery. Semin Cardiothorac Vasc Anesthesia 2004; 8(3): 227-41.
15. Feldkamp T, Kribben A. Contrast media induced nephropathy: Definition, incidence, outcome, pathophysiology, risk factors and prevention. Minerva Medica 2008; 99(2): 177-96.
16. Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: The wheel has turned 360 degrees. Acta Radiol 2008; 49(6): 646-57.
17. Gowdak LH, de Paula FJ, Cesar LA, Filho EE, Ianhez LE, Krieger EM, et al. Diabetes and coronary artery disease impose similar cardiovascular morbidity and mortality on renal transplant candidates. Nephrol Dial Transplant 2007; 22(5): 1456-61.
18. Pauly DF, Pepine CJ. Ischemic heart disease: Metabolic approaches to management. Clin Cardiol 2004; 27(8): 439-41.
19. Simmons MN, Schreiber MJ, Gill IS. Surgical renal ischemia: A contemporary overview. J Urol 2008; 180(1): 19-30.
20. Silva P. Energy and fuel substrate metabolism in the kidney. Semin Nephrol 1990; 10(5): 432-44.
21. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 1997; 33(2): 243-57.
22. Ch'en F, Clarke K, Vaughan-Jones R, Noble D. Modeling of internal pH, ion concentration, and bioenergetic changes during myocardial ischemia. Adv Exp Med Biol 1997; 430: 281-90.
23. Gores GJ, Nieminen AL, Fleishman KE, Dawson TL, Herman B, Lemasters JJ. Extracellular acidosis delays onset of cell death in ATP-depleted hepatocytes. Am J Physiol 1988; 255(3 Pt 1): C315-22.
24. Bernardi P, Broekemeier KM, Pfeiffer DR. Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerg Biomemb 1994; 26(5): 509-17.
25. Kerr PM, Suleiman MS, Halestrap AP. Reversal of permeability transition during recovery of hearts from ischemia and its enhancement by pyruvate. Am J Physiol 1999; 276(2 Pt 2): H496-502.
26. Cryer HG. Therapeutic approaches for clinical ischemia and reperfusion injury. Shock (Augusta, Ga) 1997; 8(1): 26-32.
27. Vercesi AE. Ca2+ transport and oxidative damage of mitochondria. Brazilian J medical and biological research = Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica [et al 1993; 26(5): 441-57.
28. Allen SP, Darley-Usmar VM, McCormack JG, Stone D. Changes in mitochondrial matrix free calcium in perfused rat hearts subjected to hypoxia-reoxygenation. J Mol Cellular Cardiol 1993; 25(8): 949-58.
29. Ferrari R. The role of mitochondria in ischemic heart disease. J Cardiovasc Pharmacol 1996; 28(Suppl 1): S1-10.
30. Miyata H, Lakatta EG, Stern MD, Silverman HS. Relation of mitochondrial and cytosolic free calcium to cardiac myocyte recovery after exposure to anoxia. Circ Res 1992; 71(3): 605-13.
31. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999; 341 (Pt 2): 233-49.
32. Choi DW. Ischemia-induced neuronal apoptosis. Curr Opin Neurobiol 1996; 6(5): 667-72.
33. Kohli V, Selzner M, Madden JF, Bentley RC, Clavien PA. Endothelial cell and hepatocyte deaths occur by apoptosis after ischemia-reperfusion injury in the rat liver. Transplant 1999; 67(8): 1099-105.
34. Maulik N, Yoshida T, Das DK. Oxidative stress developed during the reperfusion of ischemic myocardium induces apoptosis. Free Rradical Biol Med 1998; 24(5): 869-75.
35. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, et al. Apoptosis in the failing human heart. New Engl J Med 1997; 336(16): 1131-41.
36. Eckardt KU, Rosenberger C, Jurgensen JS, Wiesener MS. Role of hypoxia in the pathogenesis of renal disease. Blood Purific 2003; 21(3): 253-7.
37. Rosenberger C, Rosen S, Shina A, Bernhardt W, Wiesener MS, Frei U, et al. Hypoxia-inducible factors and tubular cell survival in isolated perfused kidneys. Kidney Int 2006; 70(1): 60-70.
38. Rosenberger C, Rosen S, Shina A, Frei U, Eckardt KU, Flippin LA, et al. Activation of hypoxia-inducible factors ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney. Nephrol Dial Transplant 2008; 23(11): 3472-8.
39. [39] Hill P, Shukla D, Tran MG, Aragones J, Cook HT, Carmeliet P, et al. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J Am Soc Nephrol 2008; 19(1): 39-46.
40. Cruzado JM, Torras J, Riera M, Herrero I, Hueso M, Espinosa L, et al. Influence of nephron mass in development of chronic renal failure after prolonged warm renal ischemia. Am J Physiol 2000; 279(2): F259-69.
41. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985; 249(3 Pt 2): F324-37.
42. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: A paradigm shift in nephrology. Kidney Int 1996; 49(6): 1774-7.
43. Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 1998; 53(6): 1608-15.
44. Rauen U, de Groot H. New insights into the cellular and molecular mechanisms of cold storage injury. J Investig Med 2004; 52(5): 299-309.
45. Jamieson RW, Friend PJ. Organ reperfusion and preservation. Front Biosci 2008; 13: 221-35.
46. Salahudeen AK. Cold ischemic injury of transplanted kidneys: New insights from experimental studies. Am J Physiol 2004; 287(2): F181-7.
47. Hicks M, Hing A, Gao L, Ryan J, Macdonald PS. Organ preservation. Methods in Mol Biol (Clifton, NJ) 2006; 333: 331-74.
48. Mikhalski D, Wissing KM, Ghisdal L, Broeders N, Touly M, Hoang AD, et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. Transplantion 2008; 85(7 Suppl): S3-9.
49. Opelz G, Dohler B. Multicenter analysis of kidney preservation. Transplantation 2007; 83(3): 247-53.
50. Pratschke J, Weiss S, Neuhaus P, Pascher A. Review of nonimmunological causes for deteriorated graft function and graft loss after transplantation. Transplant Int 2008; 21(6): 512-22.
51. Sulikowski T, Domanski L, Ciechanowski K, Adler G, Pawlik A, Safranow K, et al. Effect of trimetazidine on xanthine oxidoreductase expression in rat kidney with ischemia - reperfusion injury. Arch Med Res 2008; 39(4): 459-62.
52. Granger DN, Rutili G, McCord JM. Superoxide radicals in feline intestinal ischemia. Gastroenterology 1981; 81(1): 22-9.
53. Coward RJ, Welsh GI, Yang J, Tasman C, Lennon R, Koziell A, et al. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005; 54(11): 3095-102.
54. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Investig 1995; 96(4): 1802-14.
55. Shah SV, Baliga R, Rajapurkar M, Fonseca VA. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18(1): 16-28.
56. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994; 43(5): 676-83.
57. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267(21): 14998-5004.
58. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Investig 1995; 96(3): 1395-403.
59. Inagi R, Yamamoto Y, Nangaku M, Usuda N, Okamato H, Kurokawa K, et al. A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice. Diabetes 2006; 55(2): 356-66.
60. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol 2005; 289(2): F420-30.
61. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Investig 1998; 101(5): 1142-7.
62. Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: Involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chemico-Biol Interactions 1998; 111-112: 137-51.
63. Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, et al. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005; 280(47): 39616-26.
64. Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998; 54(3): 775-84.
65. Craven PA, Studer RK, Felder J, Phillips S, DeRubertis FR. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes 1997; 46(4): 671-81.
66. Koya D, Lee IK, Ishii H, Kanoh H, King GL. Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol 1997; 8(3): 426-35.
67. Park SH, Choi HJ, Lee JH, Woo CH, Kim JH, Han HJ. High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-beta 1. Kidney Int 2001; 59(5): 1695-705.
68. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 2003; 14(8 Suppl 3): S250-3.
69. Kang BP, Frencher S, Reddy V, Kessler A, Malhotra A, Meggs LG. High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism. Am J Physiol 2003; 284(3): F455-66.
70. Noronha IL, Fujihara CK, Zatz R. The inflammatory component in progressive renal disease - are interventions possible? Nephrol Dial Transplant 2002; 17(3): 363-8.
71. Shi H, Patschan D, Epstein T, Goligorsky MS, Winaver J. Delayed recovery of renal regional blood flow in diabetic mice subjected to acute ischemic kidney injury. Am J Physiol 2007; 293(5): F1512-7.
72. Ishii N, Patel KP, Lane PH, Taylor T, Bian K, Murad F, et al. Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol 2001; 12(8): 1630-9.
73. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25(8): 634-41.
74. Bittigau P, Ikonomidou C. Glutamate in neurologic diseases. J Child Neurol 1997; 12(8): 471-85.
75. M. Spedding LP. Role of lipids and lipids metabolites in myocardial ischemia. In: Paratt JR, Ed. London: McMillan 1992; 170-88.
76. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cellular Cardiol 1994; 26(8): 949-58.
77. Pogatsa G. Metabolic energy metabolism in diabetes: Therapeutic implications. Coron Artery Dis 2001; 12 (Suppl 1): S29-33.
78. Stanley WC. Rationale for a metabolic approach in diabetic coronary patients. Coron Artery Dis 2005; 16 (Suppl 1): S11-5.
79. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86(5): 580-8.
80. Ancerewicz J, Migliavacca E, Carrupt PA, Testa B, Bree F, Zini R, et al. Structure-property relationships of trimetazidine derivatives and model compounds as potential antioxidants. Free Radical Biol Med 1998; 25(1): 113-20.
81. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Cclin Pharmacol 1994; 37(3): 279-88.
82. Kaur H, Padi SS, Chopra K. Attenuation of renal ischemia-reperfusion injury by trimetazidine: Evidence of an in vivo antioxidant effect. Methods Find Exp Clin Pharmacol 2003; 25(10): 803-9.
83. Maridonneau-Parini I, Harpey C. Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985; 20(2): 148-51.
84. Tselepis A, Doulias P, Lourida E, Glantzounis G, Tsimoyiannis E, Galaris D. Trimetazidine protects low-density lipoproteins from oxidation and cultured cells exposed to H(2)O(2) from DNA damage. Free Radical Biol Med 2001; 30(12): 1357-64.
85. Reymond F, Steyaert G, Carrupt PA, Morin D, Tillement JP, Girault HH, et al. The pH-partition profile of the anti-ischemic drug trimetazidine may explain its reduction of intracellular acidosis. Pharma Res 1999; 16(5): 616-24.
86. Maruyama K, Hara A, Hashizume H, Ushikubi F, Abiko Y. Ranolazine attenuates palmitoyl-L-carnitine-induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol 2000; 52(6): 709-15.
87. Stacpoole PW. The pharmacology of dichloroacetate. Metab Clin Exp 1989; 38(11): 1124-44.
88. Whitehouse S, Cooper RH, Randle PJ. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J 1974; 141(3): 761-74.
89. Morin D, Hauet T, Spedding M, Tillement J. Mitochondria as target for antiischemic drugs. Adv Drug Deliv Rev 2001; 49(1-2): 151-74.
90. Jeffrey FM, Alvarez L, Diczku V, Sherry AD, Malloy CR. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J Cardiovasc Pharmacol 1995; 25(3): 469-72.
91. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996; 52(2): 273-80.
92. Higgins AJ, Morville M, Burges RA, Gardiner DG, Page MG, Blackburn KJ. Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate oxidation and protects the ischaemic rat heart. Life Sci 1980; 27(11): 963-70.
93. Lopaschuk GD, McNeil GF, McVeigh JJ. Glucose oxidation is stimulated in reperfused ischemic hearts with the carnitine palmitoyltransferase 1 inhibitor, Etomoxir. Mol Cell Biochem 1989; 88(1-2): 175-9.
94. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1995; 1271(1): 195-204.
95. Crestanello JA, Kamelgard J, Lingle DM, Mortensen SA, Rhode M, Whitman GJ. Elucidation of a tripartite mechanism underlying the improvement in cardiac tolerance to ischemia by coenzyme Q10 pretreatment. J Thorac Cardiovasc Surg 1996; 111(2): 443-50.
96. Hano O, Thompson-Gorman SL, Zweier JL, Lakatta EG. Coenzyme Q10 enhances cardiac functional and metabolic recovery and reduces Ca2+ overload during postischemic reperfusion. Am J Physiol 1994; 266(6 Pt 2): H2174-81.
97. Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J 2000; 139(2 Pt 3): S115-9.
98. Mallet RT. Pyruvate: Metabolic protector of cardiac performance. Proc Soc Exp Biol Med Soc Exp Biol Med (New York, NY) 2000; 223(2): 136-48.
99. Spedding M, Tillement JP, Morin D, Le Ridant A. [Medicines interacting with mitochondria: Anti-ischemic effects of trimetazidine]. Therapie 1999; (5): 627-35.
100. Grynberg A. [Modifications in myocardial energy metabolism in diabetic patients]]. Diabetes Metab 2001; 27(5 Pt 2): S12-9.
101. Belardinelli R, Cianci G, Gigli M, Mazzanti M, Lacalaprice F. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol 2008; 51(6): 611-5.
102. Fragasso G, Palloshi A, Bassanelli G, Steggerda R, Montano C, Margonato A. [Heart disease and diabetes: From pathophysiology to therapeutic options]. Ital Heart J 2004; 5 (Suppl 2): 4S-15S.
103. Marzilli M. Management of ischaemic heart disease in diabetic patients - is there a role for cardiac metabolic agents? Curr Med Res Opin 2001; 17(3): 153-8.
104. Rodriguez Padial L, Maicas Bellido C, Velazquez Martin M, Gil Polo B. [A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease. DIETRIC study]. Revista Clin Espanola 2005; 205(2): 57-62.
105. Rosano GM, Vitale C, Fragasso G. Metabolic therapy for patients with diabetes mellitus and coronary artery disease. Am J Cardiol 2006; 98(5A): 14J-8J.
106. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: A double-blind placebo-controlled study. Cardiovasc Diabetol 2003; 2: 16.
107. Rosano GM, Vitale C, Volterrani M, Fini M. Metabolic therapy for the diabetic patients with ischaemic heart disease. Coron Artery Dis 2005; 16 (Suppl 1): S17-21.
108. Szwed H, Sadowski Z, Pachocki R, Domzal-Bochenska M, Szymczak K, Szydlowski Z, et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs The/sponsored by the Int Soc Cardiovasc Pharmacother 1999; 13(3): 217-22.
109. Cano C, Bermudez VJ, Medina MT, Bermudez FA, Ambard MJ, Souki AJ, et al. Trimetazidine diminishes fasting glucose in rats with fasting hyperglycemia: A preliminary study. Am J Therapeut 2003; 10(6): 444-6.
110. Marazzi G, Wajngarten M, Vitale C, Patrizi R, Pelliccia F, Gebara O, et al. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. Int J Cardiol 2007; 120(1): 79-84.
111. Marzilli M. Clinical benefits of a metabolic approach in the management of coronary patients. Rev Port Cardiol 2000; 19 Suppl 5: V25-30.
112. Ikizler M, Erkasap N, Dernek S, Batmaz B, Kural T, Kaygisiz Z. Trimetazidine-induced enhancement of myocardial recovery during reperfusion: A comparative study in diabetic and non-diabetic rat hearts. Arch Med Res 2006; 37(6): 700-8.
113. Belardinelli R, Lacalaprice F, Faccenda E, Volpe L. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil 2008; 15(5): 533-40.
114. Pascale C, Fornengo P, Epifani G, Bosio A, Giacometto F. Cardioprotection of trimetazidine and anthracycline-induced acute cardiotoxic effects. Lancet 2002; 359(9312): 1153-4.
115. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am heart J 2003; 146(5): E18.
116. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet 2006; 45(5): 469-91.
117. Ambrosi P, Andrejak M, Drici MD, Herpin D, Pithois-Merli I. [The best of Clin Pharmacol in 2004]. Arch Mal Coeur Vaiss 2005; 98 Spec No 1: 51-5.
118. Cooper-DeHoff R, Pepine CJ. Ranolazine is associated with cardiovascular and metabolic improvement: A win-win for patients with diabetes. Eur Heart J 2006; 27(1): 5-6.
119. McCormack JG, Stanley WC, Wolff AA. Ranolazine: A novel metabolic modulator for the treatment of angina. Gen Pharmacol 1998; 30(5): 639-45.
120. Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002; 27(7): 621-36.
121. Wang JX, Maruyama K, Murakami M, Endo T, Komatsu H, Akahane M. Antianginal effects of ranolazine in various experimental models of angina. Arzneimittel-Forschung 1999; 49(3): 193-9.
122. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27(1): 42-8.
123. Bhandari B, Subramanian L. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders. Recent Patents Cardiovasc Drug Dis 2007; 2(1): 35-9.
124. Siddiqui MA, Keam SJ. Spotlight on ranolazine in chronic stable angina pectoris. Am J Cardiovasc Drugs 2006; 6(5): 357-9.
125. Siddiqui MA, Keam SJ. Ranolazine: A review of its use in chronic stable angina pectoris. Drugs 2006; 66(5): 693-710.
126. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: The Ranolazine Open Label Experience (ROLE). J Am College Cardiol 2007; 49(10): 1027-34.
127. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circ 2007; 116(15): 1647-52.
128. McAllister A, Allison SP, Randle PJ. Effects of dichloroacetate on the metabolism of glucose, pyruvate, acetate, 3-hydroxybutyrate and palmitate in rat diaphragm and heart muscle in vitro and on extraction of glucose, lactate, pyruvate and free fatty acids by dog heart in vivo. Biochem J 1973; 134(4): 1067-81.
129. Stacpoole PW. Review of the pharmacologic and therapeutic effects of diisopropylammonium dichloroacetate (DIPA). J Clin Pharmacol J N Drugs 1969; 9(5): 282-91.
130. Stacpoole PW, Felts JM. Effects of diisopropylammonium dichloroacetate on glucose metabolism. Proc Western Pharmacol Soc 1969; 12: 111-3.
131. Stacpoole PW, Felts JM. Diisopropylammonium dichloroacetate (DIPA) and sodium dichloracetate (DCA): Effect on glucose and fat metabolism in normal and diabetic tissue. Metabolism: Clin Exp 1970; 19(1): 71-8.
132. Crabb DW, Yount EA, Harris RA. The metabolic effects of dichloroacetate. Metabolism: Clin Exp 1981; 30(10): 1024-39.
133. Bersin RM, Stacpoole PW. Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am heart J 1997; 134(5 Pt 1): 841-55.
134. McVeigh JJ, Lopaschuk GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 1990; 259(4 Pt 2): H1079-85.
135. Schoder H, Knight RJ, Kofoed KF, Schelbert HR, Buxton DB. Regulation of pyruvate dehydrogenase activity and glucose metabolism in post-ischaemic myocardium. Biochim Biophys Acta 1998; 1406(1): 62-72.
136. Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K, et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am College Cardiol 1994; 23(7): 1617-24.
137. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. New Engl J Med 1992; 327(22): 1564-9.
138. Wargovich TJ, MacDonald RG, Hill JA, Feldman RL, Stacpoole PW, Pepine CJ. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am J Cardiol 1988; 61(1): 65-70.
139. Marazzi G, Volterrani M, Rosano GM. Metabolic agents in the management of diabetic coronary patients: A new era. International J Cardiol 2008; 127(1): 124-5.
140. Konishi T, Nakamura Y, Konishi T, Kawai C. Improvement in recovery of left ventricular function during reperfusion with coenzyme Q10 in isolated working rat heart. Cardiovasc Res 1985; 19(1): 38-43.
141. Sanbe A, Tanonaka K, Niwano Y, Takeo S. Improvement of cardiac function and myocardial energy metabolism of rats with chronic heart failure by long-term coenzyme Q10 treatment. J Pharmacol Exp Therapeut 1994; 269(1): 51-6.
142. Al-Thakafy HS, Khoja SM, Al-Marzouki ZM, Zailaie MZ, Al- Marzouki KM. Alterations of erythrocyte free radical defense system, heart tissue lipid peroxidation, and lipid concentration in streptozotocin-induced diabetic rats under coenzyme Q10 supplementation. Saudi Med J 2004; 25(12): 1824-30.
143. Coldiron AD, Jr., Sanders RA, Watkins JB, 3rd. Effects of combined quercetin and coenzyme Q(10) treatment on oxidative stress in normal and diabetic rats. J Biochem Mol Toxicol 2002; 16(4): 197-202.
144. Modi K, Santani DD, Goyal RK, Bhatt PA. Effect of coenzyme Q10 on catalase activity and other antioxidant parameters in streptozotocin- induced diabetic rats. Biol Trace Element Res 2006; 109(1): 25-34.
145. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. BioFactors (Oxford, England) 1999; 9(2-4): 273-84.
146. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Molecular Aspects Med 1997; 18 (Suppl): S159-68.
147. Salles JE, Moises VA, Almeida DR, Chacra AR, Moises RS. Myocardial dysfunction in mitochondrial diabetes treated with Coenzyme Q10. Diabetes Res Clin Pract 2006; 72(1): 100-3.
148. Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 2002; 45(3): 420-6.
149. Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: A controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002; 56(11): 1137-42
150. Chew GT, Watts GF. Coenzyme Q10 and diabetic endotheliopathy: Oxidative stress and the 'recoupling hypothesis'. QJM 2004; 97(8): 537-48.
151. Hodgson JM, Watts GF. Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. BioFactors (Oxford, England) 2003; 18(1-4): 129-36.
152. Lamson DW, Plaza SM. Mitochondrial factors in the pathogenesis of diabetes: A hypothesis for treatment. Altern Med Rev 2002; 7(2): 94-111.
153. Bonakdar RA, Guarneri E. Coenzyme Q10. Am Family Phys 2005; 72(6): 1065-70.
154. Lodge JP, Lam FT, Perry SL, Giles GR. Ranolazine--a new drug with beneficial effects on renal preservation. Transplantation 1990; 50(5): 755-9.
155. Dlugosz A, Kuzniar J, Sawicka E, Marchewka Z, Lembas- Bogaczyk J, Sajewicz W, et al. Oxidative stress and coenzyme Q10 supplementation in renal transplant recipients. Int Urol Nephrol 2004; 36(2): 253-8.
156. Hauet T, Mothes D, Goujon JM, Caritez JC, Carretier M, le Moyec L, et al. Trimetazidine prevents renal injury in the isolated perfused pig kidney exposed to prolonged cold ischemia. Transplantation 1997; 64(7): 1082-6.
157. Goujon JM, Vandewalle A, Baumert H, Carretier M, Hauet T. Influence of cold-storage conditions on renal function of autotransplanted large pig kidneys. Kidney international 2000; 58(2): 838- 50.
158. Hauet T, Goujon JM, Vandewalle A, Baumert H, Lacoste L, Tillement JP, et al. Trimetazidine reduces renal dysfunction by limiting the cold ischemia/reperfusion injury in autotransplanted pig kidneys. J Am Soc Nephrol 2000; 11(1): 138-48.
159. Cook-Mills JM. VCAM-1 signals during lymphocyte migration: Role of reactive oxygen species. Mol Immunol 2002; 39(9): 499-508.
160. Hauet T, Baumert H, Amor IB, Gibelin H, Tallineau C, Eugene M, et al. Pharmacological limitation of damage to renal medulla after cold storage and transplantation by trimetazidine. J Pharmacol Exp Therapeut 2000; 292(1): 254-60.
161. Faure JP, Baumert H, Han Z, Goujon JM, Favreau F, Dutheil D, et al. Evidence for a protective role of trimetazidine during cold ischemia: Targeting inflammation and nephron mass. Biochem Pharmacol 2003; 66(11): 2241-50.
162. Inci I, Dutly A, Boehler A, Weder W. Recipient treatment with trimetazidine improves graft function and protects the energy status after lung transplantation. J Heart Lung Transplant 2001; 20(2): 153-4.
163. Inci I, Dutly A, Rousson V, Boehler A, Weder W. Trimetazidine protects the energy status after ischemia and reduces reperfusion injury in a rat single lung transplant model. J Thorac Cardiovasc Surg 2001; 122(6): 1155-61.
164. Castedo E, Segovia J, Escudero C, Olmedilla B, Granado F, Blas C, et al. [Ischemia-reperfusion injury during experimental heart transplantation. Evaluation of trimetazidine's cytoprotective effect]. Revista Esp Cardiol 2005; 58(8): 941-50.
165. Ruiz-Meana M. [Trimetazidine, oxidative stress, and cell injury during myocardial reperfusion]. Revista Esp Cardiol 2005; 58(8): 895-7.
166. Ben Mosbah I, Casillas-Ramirez A, Xaus C, Serafin A, Rosello- Catafau J, Peralta C. Trimetazidine: Is it a promising drug for use in steatotic grafts? World J Gastroenterol 2006; 12(6): 908-14.
167. Casillas-Ramirez A, Mosbah IB, Ramalho F, Rosello-Catafau J, Peralta C. Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation. Life Sci 2006; 79(20): 1881-94.
168. Zhou XJ, Rakheja D, Yu X, Saxena R, Vaziri ND, Silva FG. The aging kidney. Kidney Int 2008; 74(6): 710-20.
169. Flechner SM. Cyclosporine: A new and promising immunosuppressive agent. Urologic clin North Am 1983; 10(2): 263-75.
170. Calne RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2(8151): 1033-6.
171. Kahan BD. Cyclosporine nephrotoxicity: Pathogenesis, prophylaxis, therapy, and prognosis. Am J Kidney Dis 1986; 8(5): 323-31.
172. Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplanation 1994; 58(2): 170-8.
173. Erer B, Polchi P, Lucarelli G, Angelucci E, Baronciani D, Galimberti M, et al. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: Analysis of risk factors. Bone Marrow Transplant 1996; 18(1): 157-62.
174. Mueller AR, Platz KP, Bechstein WO, Schattenfroh N, Stoltenburg- Didinger G, Blumhardt G, et al. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplanation 1994; 58(2): 155-70.
175. Wijdicks EF, Wiesner RH, Krom RA. Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression. Neurology 1995; 45(11): 1962-4.
176. Canafax DM, Torres A, Fryd DS, Heil JE, Strand MH, Ascher NL, et al. The effects of delayed function on recipients of cadaver renal allografts. A study of 158 patients randomized to cyclosporine or ALG-azathioprine. Transplantation 1986; 41(2): 177-81.
177. Lennard TW, Parrott NR, Wilson RG, Proud G, Farndon JR, Simpson JM, et al. Renal transplantation: The non-starters. Br J Sur 1988; 75(6): 570-2.
178. Creagh T, Lanigan D, Dolan J, Tormey W, Walshe JJ, Bouchier- Hayes D. Pharmacological manipulation of acute cyclosporin ischemic renal injury with trimetazidine. J Urol 1993; 149(4): 915-7.
179. Zini R, Simon N, Morin C, d'Athis P, Tillement JP. Inhibition of rat cerebral mitochondrial respiration by cyclosporins A, D, and G and restoration with trimetazidine. C R Acad Sci Gen 1996; 319(12): 1087-92.
180. Elimadi A, Morin D, Sapena R, Chauvet-Monges AM, Crevat A, Tillement JP. Comparison of the effects of cyclosporine A and trimetazidine on Ca(2+)-dependent mitochondrial swelling. Fundam Clin Pharmacol 1997; 11(5): 440-7.
181. Salducci MD, Chauvet-Monges AM, Tillement JP, Albengres E, Testa B, Carrupt P, et al. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria. J Pharmacol Exp Therapeut 1996; 277(1): 417-22.
182. Tillement JP, Crevat A, Testa B, Le Ridant A. [Pharmacological modulation of mitochondrial oxidative phosphorylation: Inhibition by cyclosporine A, restoration by trimetazidine]. Ann Pharmaceut Francaises 1996; 54(6): 268-71.
183. Albengres E, Tillement JP, d'Athis P, Salducci D, Chauvet-Monges AM, Crevat A. Lack of pharmacodynamic interaction between trimetazidine and cyclosporin A in human lymphoproliferative and mouse delayed hypersensitivity response models. Fundam Clin Pharmacol 1996; 10(3): 264-8.
184. Simon N, Brunet P, Roumenov D, Dussol B, Barre J, Duche JC, et al. Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients. Br J Clin Pharmacol 1997; 44(6): 591-4.
185. Simon N, Tillement JP, Albengres E, Jaber K, Hestin D, Roux F, et al. Potential interest of anti-ischemic agents for limiting cyclosporin A nephrotoxicity. Int J Clin Pharmacol Res 1997; 17(4): 133-42.
186. Chander V, Singh D, Chopra K. Attenuation of glycerol-induced acute renal failure in rats by trimetazidine and deferoxamine. Pharmacology 2003; 67(1): 41-8. 187 Singh D, Chander V, Chopra K. Car vedilol and trimetazidine attenuates ferric nitrilotriacetate-induced oxidative renal injury in rats. Toxicology 2003; 191(2-3): 143-51.
187. Argaud L, Gomez L, Gateau-Roesch O, Couture-Lepetit E, Loufouat J, Robert D, et al. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2005; 39(6): 893-9.
188. Elimadi A, Settaf A, Morin D, Sapena R, Lamchouri F, Cherrah Y, et al. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function. J Pharmacol Exp Therapeut 1998; 286(1): 23-8.
189. Morin D, Elimadi A, Sapena R, Crevat A, Carrupt PA, Testa B, et al. Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. Br J Pharmacol 1998; 123(7): 1385-94.
190. Ozden A, Aybek Z, Saydam N, Calli N, Saydam O, Duzcan E, et al. Cytoprotective effect of trimetazidine on 75 min warm renal ischemia-reperfusion injury in rats. Eur Surgl Res 1998; 30(4): 227-34.
191. Grekas D, Dioudis C, Papageorgiou G, Iliadis S, Zilidis C, Alivanis P, et al. Lipid peroxidation after acute renal ischemia and reperfusion in rats: The effect of trimetazidine. Renal Fail 1996; 18(4): 545-52.
192. Karayaylali I, Emre M, Seyrek N, Yildiz SM, Erdogan S, Balal M, et al. Nonsynergistic effects of trimetazidine and selenium combination therapy on renal ischemic-reperfusion injury in rats. Adv Therapy 2004; 21(1): 47-60.
193. Singh D, Chopra K. Effect of trimetazidine on renal ischemia/ reperfusion injury in rats. Pharmacol Res 2004; 50(6): 623-9.
194. Domanski L, Sulikowski T, Safranow K, Pawlik A, Olszewska M, Chlubek D, et al. Effect of trimetazidine on the nucleotide profile in rat kidney with ischemia-reperfusion injury. Eur J Pharm Sci 2006; 27(4): 320-7.
195. Blardi P, de Lalla A, Volpi L, Auteri A, Di Perri T. Increase of adenosine plasma levels after oral trimetazidine: A pharmacological preconditioning? Pharmacol Res 2002; 45(1): 69-72.
196. Veitch K, Maisin L, Hue L. Trimetazidine effects on the damage to mitochondrial functions caused by ischemia and reperfusion. Am J Cardiol 1995; 76(6): 25B-30.
197. Abdel-Salam OM, El-Batran S. Pharmacological investigation of trimetazidine in models of inflammation, pain and gastric injury in rodents. Pharmacology 2005; 75(3): 122-32.
198. El Banani H, Bernard M, Baetz D, Cabanes E, Cozzone P, Lucien A, et al. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res 2000; 47(4): 688-96.
199. Jayle C, Favreau F, Zhang K, Doucet C, Goujon JM, Hebrard W, et al. Comparison of protective effects of trimetazidine against experimental warm ischemia of different durations: Early and longterm effects in a pig kidney model. Am J Physiol 2007; 292(3): F1082-93.
200. Hauet T, Goujon JM, Baumert H, Petit I, Carretier M, Eugene M, et al. Polyethylene glycol reduces the inflammatory injury due to cold ischemia/reperfusion in autotransplanted pig kidneys. Kidney Int 2002; 62(2): 654-67.
201. Penfield JG, Wang Y, Li S, Kielar MA, Sicher SC, Jeyarajah DR, et al. Transplant surgery injury recruits recipient MHC class II positive leukocytes into the kidney. Kidney Int 1999; 56(5): 1759-69.
202. Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol 2008; 3(1): 288-96.
203. Cau J, Favreau F, Tillement JP, Lerman LO, Hauet T, Goujon JM. Trimetazidine reduces early and long-term effects of experimental renal warm ischemia: A dose effect study. J Vasc Surg 2008; 47(4): 852-60
204. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365(9457): 417-30.
205. Lameire N, Van Biesen W, Vanholder R. The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol 2006; 2(7): 364-77.
206. Leblanc M, Kellum JA, Gibney RT, Lieberthal W, Tumlin J, Mehta R. Risk factors for acute renal failure: Inherent and modifiable risks. Curr Opin Crit Care 2005; 11(6): 533-6.
207. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 2006; 6(4): 652-8.
208. McLaren AJ, Friend PJ. Trends in organ preservation. Transpl Int 2003; 16(10): 701-8.
209. Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 2008; 14(10): 946-52.
210. Thompson CS. Animal models of diabetes mellitus: Relevance to vascular complications. Curr Pharm Des 2008; 14(4): 309-24.
211. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T. Receptor for advanced glycation end products (RAGE): A novel therapeutic target for diabetic vascular complication. Curr Pharm Des 2008; 14(5): 487-95.